We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Multiplex Immunoassay Developed for Chagas Disease

By LabMedica International staff writers
Posted on 21 Apr 2016
Print article
Image: The SensoSpot microarray analyzer (Photo courtesy of Sensovation).
Image: The SensoSpot microarray analyzer (Photo courtesy of Sensovation).
Different tests are available for the diagnosis of Chagas disease in the clinic or for screening of blood donations. Direct detection of parasite Trypanosoma cruzi in the blood is performed by microscopy, hemoculture, xenodiagnoses, or detection of the parasite’s nucleic acids.

These assays are highly specific but lack sensitivity in the chronic stage during which parasites load in the blood is reduced and therefore, diagnosis of T. cruzi infection is usually made indirectly by the detection of specific antibodies to T. cruzi antigens using enzyme-linked immunosorbent assays.

Scientists from InfYnity Biomarkers (Lyon, France) working with their Brazilian colleagues tested 248 positive samples T. cruzi, 94 unscreened blood donors’ samples from non-endemic area, 49 seronegative blood donors, 7 false-positive and 3 doubtful samples. They designed a novel array of twelve antigens and printed these antigens onto 96-well plates using a sciFLEXARRAYER printing system (SCIENION; Berlin, Germany). Multi- cruzi Chagas ELISA assays were performed and each plate was imaged then analyzed using the SensoSpot Microarray Analyzers (Sensovation; Radolfzell, Germany).

Among the 200 cardiomyopathy samples, only 194 could be characterized as either negative (67%) or positive (33%) by polymerase chain reaction (PCR). Additionally, among the 48 screening-positive blood donors, 34 were PCR negative (71%) and 14 were PCR positive (29%). PCR techniques were different for both populations. The observed reactivities were analyzed to propose a decision-tree algorithm that correctly classifies all the samples, with the potential to discriminate false-positive results and sticky samples. The team observed that antibodies levels (Sum of all antigens) were significantly higher for PCR positive than for PCR negative samples in all studied groups with Multi-cruzi Chagas ELISA.

The authors concluded that the results described in their study indicate that the Multi-cruzi improves the serological confirmation of Chagas disease. Moreover, the “sum of all antigens” detected by Multi-cruzi could reflect parasitemia level in patients, similar to PCR signals, and could serve as an indicator of parasite clearance in longitudinal follow- ups. Validation of this assay is still required on an independent large collection of well-characterized samples including typical false-reactive samples such as Leishmaniasis. The study was published on April 1, 2016, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
InfYnity Biomarkers
SCIENION
Sensovation

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
RFID Inlay
Minidose U8 RAIN
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.